After a staid first half of FY03, P&G Hygiene & Healthcare Limited (P&G) has finally shown signs of strength in its March quarter numbers. The company has reported a strong 17% topline growth during this quarter. The company has compromised its operating margins (albeit marginally) to propel topline growth.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Earnings per share*
Current P/e ratio
Aided by almost no interest burden and lower depreciation provisioning (down 32%), the company has managed to report over 22% bottomline growth, despite a 49% growth in tax provisioning. Depreciation provisioning has gone down as the company sold its Hyderabad factory assets to a contract manufacturer in January 2003.
On a nine month basis, P&G has reported a 5% topline growth and a staid 7% bottomline growth. The significant dip in operating margins becomes apparent if one compares it against the 9mFY03 numbers (where OPM stood at 27%). It indicates that P&G has been forced to cut pricing of its products in a bid to sell more. And this seems to have worked for the company this quarter.
as a % of sales
Increase/(decrease) in stock in trade
Raw material/packaging cost
Raw material cost
Sales of P&G's core categories, i.e., Health Care (Vicks) and Feminine Hygiene (Whisper) grew by 25% during the quarter, as compared to an overall 8% growth in 9mFY03. In 9mFY03 so far, Vicks has grown by 5% and Whisper business by 13%. The growth in Whisper has largely been spearheaded by Whisper Ultra.
The company has recorded a significant growth in other income (90%) and this has propelled the bottomline in 3QFY03. We believe that P&G's sell off of its Hyderabad factory, for which P&G Singapore reimbursed the company, seems to have increased cash in the company, leading to higher other income. In the nine months comparision, other income for last year includes around Rs 73 m as extraordinary income, and therefore the dip in other income during 9mFY03.
At the current price of Rs 375 the stock trades at a P/E of 9.2x 9mFY03 annualised earnings. The valuation is on the lower side of the FMCG spectrum. This is probably because of the company's two product focus, as well as concerns regarding the parent's other 100% subsidiaries.
Procter & Gamble Hygiene and Health Care has announced the first quarter results of the financial year ended June 2017 (1QFY17). The company's sales rose by 12.5%YoY while net profit rose by 50.1% YoY during the quarter.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407